Oppenheimer Reiterates Outperform on Neurocrine Biosciences, Maintains $150 Price Target
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Jay Olson has reiterated an Outperform rating on Neurocrine Biosciences (NASDAQ:NBIX) and maintained a $150 price target.
August 04, 2023 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst has reiterated an Outperform rating on Neurocrine Biosciences and maintained a $150 price target.
The reiteration of an Outperform rating and maintenance of a high price target by a reputable analyst like Jay Olson indicates strong confidence in the company's performance. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100